Novo Nordisk Amended Proposal Values Metsera at up to $ 86.20 per Share, a Total of Approximately $ 10.0 Billion Superior to Revised Pfizer Proposal that Valued Metsera at up to $ 70.00 per Share, […]
Tag: Metsera
Metsera Issues Statement in Response to Litigation
NEW YORK, Oct. 31, 2025 /PRNewswire/ — Metsera, Inc. (NASDAQ: MTSR) (“Metsera” or the “Company”) today issued the following statement in response to litigation filed against the Company by Pfizer: “Metsera disagrees with the allegations […]
Metsera Issues Statement in Response to Litigation
NEW YORK, Oct. 31, 2025 /PRNewswire/ — Metsera, Inc. (NASDAQ: MTSR) (“Metsera” or the “Company”) today issued the following statement in response to litigation filed against the Company by Pfizer: “Metsera disagrees with the allegations […]
Metsera Issues Statement in Response to Litigation
NEW YORK, Oct. 31, 2025 /PRNewswire/ — Metsera, Inc. (NASDAQ: MTSR) (“Metsera” or the “Company”) today issued the following statement in response to litigation filed against the Company by Pfizer: “Metsera disagrees with the allegations […]
Metsera Receives Unsolicited Proposal from Novo Nordisk
Metsera Declares Novo Nordisk Proposal “Superior” Novo Nordisk Proposal Values Metsera at up to $77.75 per Share, a Total of Approximately $9 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments […]
